These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 8913337)

  • 1. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists.
    Morissette M; Grondin R; Goulet M; Bédard PJ; Di Paolo T
    J Neurochem; 1999 Feb; 72(2):682-92. PubMed ID: 9930741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.
    Morissette M; Goulet M; Soghomonian JJ; Blanchet PJ; Calon F; Bédard PJ; Di Paolo T
    Brain Res Mol Brain Res; 1997 Oct; 49(1-2):55-62. PubMed ID: 9387863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
    Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
    Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis.
    Goulet M; Morissette M; Calon F; Blanchet PJ; Falardeau P; Bédard PJ; Di Paolo T
    Neuroscience; 1997 Jul; 79(2):497-507. PubMed ID: 9200732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys.
    Ouattara B; Gasparini F; Morissette M; Grégoire L; Samadi P; Gomez-Mancilla B; Di Paolo T
    J Neurochem; 2010 May; 113(3):715-24. PubMed ID: 20132464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
    Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
    Riahi G; Morissette M; Parent M; Di Paolo T
    Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Mov Disord; 2006 Jan; 21(1):9-17. PubMed ID: 16127720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
    Bédard PJ; Gomez-Mancilla B; Blanchette P; Gagnon C; Falardeau P; DiPaolo T
    Adv Neurol; 1993; 60():113-8. PubMed ID: 8093573
    [No Abstract]   [Full Text] [Related]  

  • 15. Subthalamotomy-induced changes in dopamine receptors in parkinsonian monkeys.
    Jourdain VA; Morin N; Morissette M; Grégoire L; Di Paolo T
    Exp Neurol; 2014 Nov; 261():816-25. PubMed ID: 25172808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats.
    Criswell HE; Johnson KB; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1993 May; 265(2):1001-10. PubMed ID: 8098756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys.
    Domino EF; Sheng J
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1387-91. PubMed ID: 8099621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
    Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No direct correlation between behaviorally active doses of the dopamine D2 agonist LY 171555 and displacement of [123I]IBZM as measured with SPECT in MPTP monkeys.
    Vermeulen RJ; Drukarch B; Verhoeff NP; Goosen C; Sahadat MC; Wolters EC; van Royen EA; Stoof JC
    Synapse; 1994 Jun; 17(2):115-24. PubMed ID: 7916490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
    Yoshimura N; Mizuta E; Yoshida O; Kuno S
    J Pharmacol Exp Ther; 1998 Jul; 286(1):228-33. PubMed ID: 9655864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.